Second radiation blast targets recurrent brain tumors

NCT ID NCT06344130

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 4 times

Summary

This early-phase trial tests a new way to give radiation to people whose glioblastoma (a severe brain cancer) has come back after initial treatment. About 28 adults will receive focused radiation over 1 to 3 weeks, with different schedules to find the safest dose. The goal is to control the tumor and improve survival, but the study is small and exploratory.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiation therapy (re-irradiation)
What this could lead to: If successful, this could establish a safer, more effective radiation schedule to control recurrent glioblastoma and potentially extend survival.
What could go wrong: This is a very early phase 1 trial with only 28 participants, so results may not apply broadly. Re-irradiation carries risks of brain damage, and the tumor may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) glioblastoma glioma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASTROCYTOMA GLIOMA RECURRENT GLIOBLASTOMA

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.